TAK1 kinase inhibitors, compositions, and uses related thereto

Patent metadata

Field	Value
Publication number	US-10093609-B2
Application number	US-201715694982-A
Country	US
Kind code	B2
Filing date	Sep 4, 2017
Priority date	Jul 19, 2011
Publication date	Oct 9, 2018
Grant date	Oct 9, 2018

Abstract

The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I, pharmaceutical compositions having a compound of formula I, and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula I to a subject in need thereof.

First claim

The invention claimed is:

1. A method of treating cancer comprising administering a pharmaceutical composition comprising a compound of formula IC or salt thereof to a subject in need thereof,
wherein the cancer is selected from breast cancer, prostate cancer, lung cancer, colon cancer, liver cancer, ovarian cancer, cervical cancer, pancreatic cancer, renal cancer, thyroid cancer, melanoma, myeloma, lymphoma, leukemia, and neuroblastoma,
wherein formula IC is,

R1 is hydrogen, hydroxy, alkyl, alkoxy, carbocyclyl, aryl, or heterocyclyl, wherein R1 is optionally substituted with one or more, the same or different, R10;
R2 is formyl, carboxy, or phosphonate, wherein R2 is optionally substituted with one or more, the same or different, R10;
R5 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R5 is optionally substituted with one or more, the same or different, R10;
R6 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R6 is optionally substituted with one or more, the same or different, R10;
R7 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R 7 is optionally substituted with one or more, the same or different, R 10 ;
R8 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R8 is optionally substituted with one or more, the same or different, R10;
R9 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R9 is optionally substituted with one or more, the same or different, R10;
R10 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R10 is optionally substituted with one or more, the same or different, R11;
R11 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R11 is optionally substituted with one or more, the same or different, R12;
R12 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R12 is optionally substituted with one or more, the same or different, R13; and
R13 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethyl sulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl.

2. The method of claim 1 , wherein the compound is selected from:
(2Z,4Z)-dimethyl 2-(3,4-dichlorophenyl)hexa-2,4-dienedioate,
(2Z,4Z)-dimethyl 2-(4-bromophenyl)hexa-2,4-dienedioate,
(2Z,4Z)-dimethyl 2-(4-iodophenyl)hexa-2,4-dienedioate, and
(2Z,4Z)-dimethyl 2-(4-nitrophenyl)hexa-2,4-dienedioate.

3. The method of claim 1 , wherein the subject is diagnosed with a tumor or malignant tumors derived from epithelial cells.

4. The method of claim 1 , further comprising administering the compound of formula IC or salt thereof in combination with an additional active agents.

5. The method of claim 4 , wherein the additional active agent is a chemotherapy agent.

6. The method of claim 5 , wherein the chemotherapy agent is cis-platin or carboplatin.

7. The method of claim 5 , wherein the chemotherapy agent is cyclophosphamide.

8. The method of claim 5 , wherein the chemotherapy agent is doxorubicin.

9. The method of claim 5 , wherein the chemotherapy agent is epirubicin.

10. The method of claim 5 , wherein the chemotherapy agent is methotrexate.

11. The method of claim 5 , wherein the chemotherapy agent is taxol or taxotere.

12. The method of claim 5 , wherein the chemotherapy agent is 5-fluorouracil or tegafur.

13. The method of claim 5 , wherein the chemotherapy agent is trastuzumab.

14. The method of claim 5 , wherein the chemotherapy agent is gemcitabine.

15. The method of claim 5 , wherein the chemotherapy agent is vinorelbine.

16. The method of claim 5 , wherein the chemotherapy agent is tamoxifen.

17. The method of claim 5 , wherein the chemotherapy agent is imatinib.

Assignees

• Univ Emory

Inventors

• Davies Huw M L
• Chennamadhavuni Spandan
• Bakin Andrei

Classifications

• C07C69/618

  having unsaturation outside the six-membered aromatic ring · CPC title

• C07D317/60

  Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D209/34

  in position 2 · CPC title

• C07C69/736

  the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring · CPC title

• C07C69/73 Primary

  of unsaturated acids · CPC title